Eisai cuts Leqembi 2027 sales forecast by half but expects 'continued growth'
Eisai has slashed 2027 sales projections for its Biogen-partnered Alzheimer’s treatment Leqembi by roughly half.
The Japanese drugmaker said it expects annual Leqembi sales to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
